COMMUNIQUÉS West-GlobeNewswire

LifeStance Health Group Announces Pricing of Secondary Public Offering
22/05/2024
SCOTTSDALE, Ariz., May 21, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health [...]
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
22/05/2024
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]
APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 for the Diagnosis of Progressive Supranuclear Palsy
22/05/2024
Fast Track Designation follows announcement in January 2024 that the U.S. Food and Drug Administration (FDA) granted a “Study May Proceed” letter for APRINOIA’s planned Phase 3 study of APN-1607 (florzolotau (18F)) in [...]
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
22/05/2024
SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the [...]
Nature Medicine se réjouit de partager l’amélioration significative de la fonction de la main et du bras après une lésion de la moelle épinière grâce à la thérapie ONWARD® ARC-EX® Therapy
21/05/2024
La thérapie ARC Therapy™ s’est révélée sûre et efficace dans le cadre d’une étude pivot mondiale* Quatre-vingt-dix pour cent des participants ont amélioré la force ou la fonction de leurs membres supérieurs* [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
21/05/2024
COPENHAGEN, Denmark, May 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on May 8, 2024, has now been terminated, as the intended number of shares [...]
LeMaitre to Present at the Jefferies Global Healthcare Conference
21/05/2024
BURLINGTON, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that George W. LeMaitre, Chairman & CEO, will present at the 2024 Jefferies Global Healthcare Conference on [...]
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
21/05/2024
Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year. Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year. Alvotech [...]
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
21/05/2024
Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year. Alvotech [...]
BioCardia Announces Reverse Stock Split
21/05/2024
SUNNYVALE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that [...]
Atrion Corporation Declares Quarterly Cash Dividend
21/05/2024
ALLEN, Texas, May 21, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced that its Board of Directors declared a quarterly dividend of $2.20 per share on its outstanding shares of Common Stock. [...]
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
21/05/2024
Updated Nanobiotix corporate strategy designed to enable long-term growth through execution of the global NBTXR3 collaboration and platforms beyond NBTXR3 Alignment of intent to transfer the sponsorship of the ongoing [...]
Nanobiotix annonce des avancees de la collaboration globale de developpement autour de NBTXR3 refletant son pipeline robuste et son approche de croissance sur le long terme
21/05/2024
Mise à jour de la stratégie d'entreprise de Nanobiotix dans la perspective d’une croissance à long terme reposant sur la mise en œuvre de la collaboration globale portant sur NBTXR3 et des plateformes autres que NBTXR3 [...]
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
21/05/2024
Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of IMPAHCT continues at more [...]
Relay Therapeutics to Participate in Upcoming Investor Conferences
21/05/2024
CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and [...]
LifeStance Health Group Announces Launch of Secondary Public Offering
21/05/2024
SCOTTSDALE, Ariz., May 21, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health [...]
Trinity Biotech plc to Announce Q1 2024 Financial Results
21/05/2024
Conference Call Scheduled for Thursday, May 23, 2024 at 8:30 AM ET. DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused [...]
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
21/05/2024
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
21/05/2024
Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease intervention Virtual [...]

Pages